GGrantIndex
Sort

17,828 grants matching crispr

MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE

$346,046
Kyle Fink · University Of California At Davis · R01 · FY2025 · NS

Hematology Training Program

$345,998
Margaret Goodell · Baylor College Of Medicine · T32 · FY2022 · DK

Use of the PBS1 Decoy System to Engineer Resistance to Plant-Parasitic Nematodes

$345,990
Roger W Innes · Indiana University · · FY2020 · BIO

Project 4: Novel epigenetic treatment of IDH mutant gliomas

$345,939
Harley I Kornblum · University Of California Los Angeles · P50 · FY2019 · CA

Transgenic Core

$345,800
Bradford B Lowell · Food Allergy Science Initiative, Inc. · P01 · FY2024 · AI

Transgenic Core

$345,800
Bradford B Lowell · Food Allergy Science Initiative, Inc. · P01 · FY2025 · AI

Functional Genomic Screening to Identify Therapeutic Targets in Human Diseases

$345,701
Ken Cheng · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

Project 3: Systematic characterization of factors controlling breast cancer progression and resistance

$345,678
Michael C Bassik · Stanford University · U54 · FY2023 · CA

Project 1: Aberrant neuronal activity and tau distribution in FTD

$345,495
Li Gan · Weill Medical Coll Of Cornell Univ · U54 · FY2020 · NS

Project 1: Aberrant neuronal activity and tau distribution in FTD

$345,493
Li Gan · Weill Medical Coll Of Cornell Univ · U54 · FY2019 · NS

Proteasome inhibitors for the treatment of solid tumors

$345,478
Alexei Kisselev · Auburn University At Auburn · R01 · FY2019 · CA

Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology.

$345,471
Christopher Werley · Q-State Biosciences, Inc. · R43 · FY2017 · MH

Modular protein switches

$345,368
Marc A Ostermeier · Johns Hopkins University · · FY2018 · ENG

Targeting the epithelial to mesenchymal transition-mediated chemoresistance in breast cancer

$345,356
Dingcheng Gao · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · CA

Targeting the epithelial to mesenchymal transition-mediated chemoresistance in breast cancer

$345,356
Dingcheng Gao · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · CA

Targeting the epithelial to mesenchymal transition-mediated chemoresistance in breast cancer

$345,356
Dingcheng Gao · Weill Medical Coll Of Cornell Univ · R01 · FY2017 · CA

Targeting the epithelial to mesenchymal transition-mediated chemoresistance in breast cancer

$345,356
Dingcheng Gao · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA

Complex Mechanisms of Mutation and Mutation Avoidance in Living Cells

$345,348
Eric Alan Josephs · University Of North Carolina Greensboro · R35 · FY2022 · GM

Epigenetic disruptions of PBDEs during neurodevelopment

$345,261
Ramendra N Saha · University Of California, Merced · R01 · FY2019 · ES

Targeting PTPN11 dependent Hematologic Malignancies

$345,230
Bill H Chang · Oregon Health & Science University · R01 · FY2023 · CA

Targeting PTPN11 dependent Hematologic Malignancies

$345,230
Bill H Chang · Oregon Health & Science University · R01 · FY2022 · CA

Mechanisms of venetoclax combination activity in acute myeloid leukemia

$345,230
Jeffrey Wallace Tyner · Oregon Health & Science University · R01 · FY2023 · CA

Mechanisms of venetoclax combination activity in acute myeloid leukemia

$345,230
Jeffrey Wallace Tyner · Oregon Health & Science University · R01 · FY2022 · CA

New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets

$345,184
James A Wells · University Of California, San Francisco · R01 · FY2024 · CA

Germline transmission of epigenetic alterations to offspring

$345,153
Ramji Kumar Bhandari · University Of Missouri-Columbia · R01 · FY2024 · ES